Zacks: Brokerages Anticipate Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Will Post Earnings of -$0.53 Per Share

Brokerages forecast that Marinus Pharmaceuticals, Inc. (NASDAQ:MRNSGet Rating) will announce ($0.53) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Marinus Pharmaceuticals’ earnings, with estimates ranging from ($1.03) to $1.47. Marinus Pharmaceuticals reported earnings of ($0.65) per share in the same quarter last year, which suggests a positive year over year growth rate of 18.5%. The firm is scheduled to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Marinus Pharmaceuticals will report full year earnings of ($2.17) per share for the current financial year, with EPS estimates ranging from ($3.75) to ($0.57). For the next year, analysts expect that the business will report earnings of ($3.89) per share, with EPS estimates ranging from ($4.87) to ($3.19). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Marinus Pharmaceuticals.

Marinus Pharmaceuticals (NASDAQ:MRNSGet Rating) last posted its quarterly earnings data on Monday, March 21st. The biopharmaceutical company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.04. Marinus Pharmaceuticals had a negative net margin of 328.21% and a negative return on equity of 145.46%. The business had revenue of $1.52 million during the quarter, compared to analyst estimates of $2.64 million. During the same quarter last year, the firm posted ($0.55) earnings per share.

MRNS has been the subject of a number of recent research reports. JMP Securities lifted their price target on shares of Marinus Pharmaceuticals from $21.00 to $22.00 and gave the stock a “market outperform” rating in a research note on Tuesday, March 22nd. HC Wainwright reissued a “buy” rating and set a $38.00 price objective on shares of Marinus Pharmaceuticals in a report on Tuesday, March 22nd. Truist Financial raised their price objective on shares of Marinus Pharmaceuticals from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, March 22nd. SVB Leerink cut their price objective on shares of Marinus Pharmaceuticals from $30.00 to $27.00 and set an “outperform” rating on the stock in a report on Tuesday, March 22nd. Finally, Zacks Investment Research raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Marinus Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $29.63.

Several hedge funds and other institutional investors have recently modified their holdings of MRNS. Suvretta Capital Management LLC boosted its position in shares of Marinus Pharmaceuticals by 20.1% during the 4th quarter. Suvretta Capital Management LLC now owns 2,638,775 shares of the biopharmaceutical company’s stock worth $31,349,000 after purchasing an additional 441,349 shares in the last quarter. Jefferies Group LLC boosted its position in shares of Marinus Pharmaceuticals by 2,774.8% in the 3rd quarter. Jefferies Group LLC now owns 439,764 shares of the biopharmaceutical company’s stock worth $5,005,000 after buying an additional 424,467 shares in the last quarter. Bleichroeder LP boosted its position in shares of Marinus Pharmaceuticals by 24.5% in the 1st quarter. Bleichroeder LP now owns 1,322,463 shares of the biopharmaceutical company’s stock worth $12,365,000 after buying an additional 259,963 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Marinus Pharmaceuticals in the 3rd quarter worth about $1,461,000. Finally, Granite Point Capital Management L.P. boosted its position in shares of Marinus Pharmaceuticals by 12.6% in the 1st quarter. Granite Point Capital Management L.P. now owns 472,056 shares of the biopharmaceutical company’s stock worth $4,414,000 after buying an additional 52,732 shares in the last quarter. Institutional investors own 80.89% of the company’s stock.

Shares of Marinus Pharmaceuticals stock opened at $5.32 on Friday. Marinus Pharmaceuticals has a 52-week low of $4.19 and a 52-week high of $19.83. The company has a 50 day moving average of $7.70 and a 200 day moving average of $9.71. The company has a current ratio of 6.91, a quick ratio of 3.25 and a debt-to-equity ratio of 1.94.

Marinus Pharmaceuticals Company Profile (Get Rating)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

See Also

Get a free copy of the Zacks research report on Marinus Pharmaceuticals (MRNS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.